5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

Peter M. Neupert net worth and biography

Peter Neupert Biography and Net Worth

Director of Laboratory Co. of America

Peter M. Neupert has served as a director of the Company since January 1, 2013. Mr. Neupert was an Operating Partner at Health Evolution Partners, a health only, middle market private equity firm, from January 2012 until June 2015. Prior to that, Mr. Neupert served as Corporate Vice President of the Microsoft Health Solutions Group from its formation in 2005 to January 2012. Mr. Neupert served on the President’s Information Technology Advisory Committee (PITAC), co-chairing the Health Information Technology Subcommittee and helping to drive the “Revolutionizing Health Care Through Information Technology” report, published in June 2004. Mr. Neupert served as the founding President and Chief Executive Officer of drugstore.com from 1998 to 2001 and as Chairman of the board of directors through September 2004. Mr. Neupert has served as a director of Adaptive Biotechnologies Corporation since December 2013 and currently serves as the Lead Independent Director. He served on the Board of Directors of Quality Systems, Inc., now known as NextGen Healthcare, Inc., from August 2013 to January 2014. He previously served as a trustee for the Fred Hutchinson Cancer Research Center and was an active member of the Institute of Medicine’s Roundtable on Value & Science-Driven Healthcare from 2007 to 2011. Mr. Neupert brings to the Board experience as a recognized expert in health information technology and perspective on how to grow shareholder value leveraging business strategies with technology. Mr. Neupert is an audit committee financial expert as a result of his experience, including his experience as CEO and Chairman of drugstore.com. Mr. Neupert serves as the Board’s lead independent director.

What is Peter M. Neupert's net worth?: The estimated net worth of Peter M. Neupert is at least $4.63 million as of August 23rd, 2023. Mr. Neupert owns 21,996 shares of Laboratory Co. of America stock worth more than $4,632,138 as of May 19th. This net worth approximation does not reflect any other investments that Mr. Neupert may own. Learn More about Peter M. Neupert's net worth.
How do I contact Peter M. Neupert?: The corporate mailing address for Mr. Neupert and other Laboratory Co. of America executives is 358 South Main Street, BURLINGTON NC, 27215. Laboratory Co. of America can also be reached via phone at (336) 229-1127 and via email at [email protected]. Learn More on Peter M. Neupert's contact information.
Has Peter M. Neupert been buying or selling shares of Laboratory Co. of America?: Peter M. Neupert has not been actively trading shares of Laboratory Co. of America during the last ninety days. Most recently, on Wednesday, February 16th, Peter M. Neupert bought 3,500 shares of Laboratory Co. of America stock. The stock was acquired at an average cost of $263.66 per share, with a total value of $922,810.00. Learn More on Peter M. Neupert's trading history.
Who are Laboratory Co. of America's active insiders?: Laboratory Co. of America's insider roster includes Kerrii Anderson (Director), Jean-Luc Belingard (Director), Brian Caveney (EVP), Glenn Eisenberg (CFO), Dwight Gilliland (Director), Paul Kirchgraber (CEO), Peter Neupert (Director), Mark Schroeder (EVP), Amy Summy (CMO), Sandra van der Vaart (EVP), Peter Wilkinson (CAO), and R. Williams (Director). Learn More on Laboratory Co. of America's active insiders.
Are insiders buying or selling shares of Laboratory Co. of America?: During the last year, insiders at the medical research company sold shares 17 times. They sold a total of 70,140 shares worth more than $15,115,203.38. The most recent insider tranaction occured on May, 14th when EVP Der Vaart Sandra D Van sold 2,000 shares worth more than $421,660.00. Insiders at Laboratory Co. of America own 0.9% of the company. Learn More about insider trades at Laboratory Co. of America.
Information on this page was last updated on 5/14/2024.

Peter M. Neupert Insider Trading History at Laboratory Co. of America

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/16/2022	Buy	3,500	$263.66	$922,810.00

Peter M. Neupert Buying and Selling Activity at Laboratory Co. of America

Laboratory Co. of America Company Overview

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

Today's Range

Now: $210.59

$208.19

$213.52

50 Day Range

MA: $208.28

$198.35

$218.53

2 Week Range

Now: $210.59

$174.20

$234.09

Volume

730,900 shs

Average Volume

755,056 shs

Market Capitalization

$17.75 billion

P/E Ratio

42.37

Dividend Yield

1.37%

Beta

1.02

Top 5 AI Stocks to Buy for 2024

From Market Moving Trends | Ad